Evidence map›Paper›PMID 38712254›Full record

ArticlebioRxiv : the preprint server for biology2024

A mitochondrial surveillance mechanism activated by

Xiaolei Liu, Sudhish A Devadiga, Robert F Stanley, Ryan Morrow, Kevin Janssen, Mathieu Quesnel-Vallières, Oz Pomp, Adam A Moverley, Chenchen Li, Nicolas Skuli and 6 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Xiaolei LiuDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Sudhish A DevadigaDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Robert F StanleyMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Ryan MorrowCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia; Philadelphia, PA, USA.
Kevin JanssenCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia; Philadelphia, PA, USA.
Mathieu Quesnel-VallièresDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.ORCID 0000-0001-9945-8123
Oz PompDepartment of Cell and Developmental Biology, Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Adam A MoverleyDepartment of Cell and Developmental Biology, Institute for Regenerative Medicine, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Chenchen LiDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Nicolas SkuliDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Martin P CarrollDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.ORCID 0000-0002-5622-3735
Jian HuangCoriell Institute for Medical Research; Camden, NJ, USA.ORCID 0000-0002-1649-0038
Douglas C WallaceCenter for Mitochondrial and Epigenomic Medicine, Children's Hospital of Philadelphia; Philadelphia, PA, USA.
Kristen W LynchDepartment of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.
Omar Abdel-WahabMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center; New York, NY, USA.
Peter S KleinDepartment of Medicine, Division of Hematology-Oncology, Perelman School of Medicine, University of Pennsylvania; Philadelphia, PA, USA.ORCID 0000-0002-2011-8538

Funding

Signal-Induced Regulation of Alternative RNA ProcessingR35GM118048 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI KRISTEN W LYNCH · 2016 to 2026
$6.6M
Maintenance and expansion of long-term hematopoietic stem cellsR01HL141759 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI KLEIN, PETER S · 2018 to 2021
$2.2M
Targeting splicing in myelodysplasia through GSK-3R56DK133258 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI KLEIN, PETER S · 2022 to 2022
$100k
Pathologic Signaling Pathways in AML CellsI01BX004662 · VA · PHILADELPHIA VA MEDICAL CENTER · PI CARROLL, MARTIN · 2021 to 2024
–
BLRD VA I01 BX004662NHLBI NIH HHS R01 HL141759NIDDK NIH HHS R56 DK133258NIGMS NIH HHS R35 GM118048
6 · The paper itself

Abstract

Splicing factor mutations are common in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), but how they alter cellular functions is unclear. We show that the pathogenic

Identifiers

PMID38712254
PMCPMC11071312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.